Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to 0.76.

  • Adma Biologics' Equity Ratio rose 2772.08% to 0.76 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.76, marking a year-over-year increase of 2772.08%. This contributed to the annual value of 0.71 for FY2024, which is 7388.62% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Equity Ratio is 0.76, which was up 2772.08% from 0.71 recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Equity Ratio peaked at 0.76 during Q3 2025, and registered a low of 0.33 during Q3 2022.
  • For the 5-year period, Adma Biologics' Equity Ratio averaged around 0.51, with its median value being 0.44 (2024).
  • In the last 5 years, Adma Biologics' Equity Ratio crashed by 2245.14% in 2022 and then surged by 7388.62% in 2024.
  • Adma Biologics' Equity Ratio (Quarter) stood at 0.51 in 2021, then fell by 14.66% to 0.44 in 2022, then dropped by 5.82% to 0.41 in 2023, then skyrocketed by 73.89% to 0.71 in 2024, then increased by 6.16% to 0.76 in 2025.
  • Its last three reported values are 0.76 in Q3 2025, 0.71 for Q2 2025, and 0.73 during Q1 2025.